About This Site

What TB-500 Safe is

TB-500 Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent compound, Thymosin Beta-4 (Tβ4). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site name is intentional. The domain "safe" in TB-500 Safe names a question — one the research literature only partially answers. We take that question seriously. Every page on this site is weighted toward what the evidence shows about safety: what the preclinical record documents, where the human data is absent, what the regulators have said, and what the cancer-risk debate in the literature has and has not resolved.

The "safe" modifier is not marketing. It is not a conclusion. It is an orientation: this is a site that takes the safety questions seriously and answers them honestly from the published record.

Our editorial approach

Every quantitative claim on this site traces to a specific peer-reviewed citation in the references list. We distinguish the TB-500 fragment (Ac-LKKTETQ) from the full Tβ4 protein throughout — a distinction that matters significantly when reading the safety data, because the only published Phase I human trial covers the full protein, not the heptapeptide fragment.^[16]

We do not overstate favorable findings. We do not minimize unfavorable ones. The angiogenesis-and-cancer concern is documented at the same weight as the tissue repair findings — because that is what the literature supports. The absence of human injectable safety data is stated directly and prominently, not buried in a footnote.

Where the research has not answered a question — and the TB-500 literature has left many open — we say so. The frequently asked questions page includes direct statements of "this has not been studied" where that is the honest answer.

What this site is not

TB-500 Safe is not a clinic and does not provide medical advice. The word "safe" in the domain name reflects a research orientation, not a clinical service. This site has no clinical staff, no practitioners, and no consultation service.

This site does not sell TB-500 or any other compound. It does not provide sourcing recommendations. Sourcing is outside this site's scope entirely.

The research findings summarized here are preclinical unless explicitly stated otherwise. Nothing on this site should be read as a recommendation for any human use of any compound. The TB-500 dosage protocols page covers research-context dosing data; it is not a dosing guide for humans.

This site does not advise athletes on substance use. TB-500 is prohibited by WADA. The TB-500 WADA status is documented on the FAQ page.